IPSCHIGH SIGNALFINANCIAL10-K

IPSC experienced dramatic revenue growth of 1,557% to $109.2M while significantly reducing losses and doubling their outstanding share count, suggesting a major business transformation or strategic transaction.

The massive revenue increase combined with substantially reduced net losses indicates either a major commercial breakthrough or a significant business combination/licensing deal. However, the doubling of outstanding shares from 86M to 180M suggests significant dilution to existing shareholders, which could offset the positive operational improvements.

Comparing 2026-03-12 vs 2025-03-19View on EDGAR →
FINANCIAL ANALYSIS

IPSC delivered extraordinary revenue growth of 1,557% to $109.2M while cutting net losses by 92% to just $9.6M, despite doubling R&D spending to $75.6M. The company dramatically improved its balance sheet by reducing total liabilities 66% to $64.8M and current liabilities by 84%, though total assets declined 37% and current assets fell 38%. This financial profile suggests a major business transformation with strong revenue momentum and improved operational efficiency, though the substantial increase in outstanding shares indicates significant shareholder dilution occurred during this period.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+1556.8%
$6.6M$109.2M

Strong top-line growth of 1556.8% — accelerating demand or successful expansion into new markets.

Capital Expenditure
Cash Flow
+450.6%
$154K$848K

Capital expenditure jumped 450.6% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
+92.4%
-$126.6M-$9.6M

Net income grew 92.4% — bottom-line growth signals improving overall business health.

R&D Expense
P&L
+90.6%
$39.7M$75.6M

R&D investment increased 90.6% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
+87.5%
-$138.1M-$17.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Liabilities
Balance Sheet
-84.4%
$129.8M$20.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-66.2%
$191.9M$64.8M

Liabilities reduced 66.2% — deleveraging improves balance sheet strength and financial flexibility.

Interest Expense
P&L
-61.5%
$1.4M$540K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Assets
Balance Sheet
-37.8%
$194.1M$120.8M

Current assets declined 37.8% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-36.7%
$353.2M$223.7M

Total assets contracted 36.7% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-19
ADDED
As of February 28, 2026, the registrant had 179,722,750 shares of Common Stock, $0.0001 par value per share, outstanding.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
BUSINESS: Overview: We are a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer.
Our beta islet, T cell and NK cell programs are allogeneic, meaning they are derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells.
We are unique in the breadth of cell types we can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ ab T cells, or ab iT cells, and iPSC- natural killer cells, or iNK cells.
+7 more — sign up free →
REMOVED
As of February 28, 2025, the registrant had 86,045,033 shares of Common Stock, $0.0001 par value per share, outstanding.
BUSINESS: Overview: We are a clinical-stage biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases and cancer.
Our natural killer, or NK, and T cell programs are allogeneic, meaning they are derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells.
We are unique in the breadth of immune effector cell types we can generate from iPSCs, including iPSC-derived natural killer cells, or iNK cells, iPSC-derived gd T cells, or gd IT cells and iPSC-derived CD4+ and CD8+ ab T cells, or ab iT cells.
Further, we have developed a feeder-free, scalable process that recapitulates normal T cell development in a dish, allowing for what we believe to be the industry-first presentation of iPSC-derived CD4+ and CD8+ CAR-T cells that demonstrate -like T cell function.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →